The heterogeneous etiology of asthma makes its diagnosis complicated. Measurement of cytokine levels could be relevant in determining the asthma phenotype, predicting severity, and identifying the treatment type. Enzyme-linked immunosorbent assay (ELISA) is one of the most reliable methods, with high sensitivity and specificity. This study aimed to determine the accuracy and utility of interleukin (IL)-13 and IL-17 A in diagnosing children with asthma. A total of 74 asthmatic and 75 healthy children were enrolled in this case-control study between 10/2019 and 3/2021. Sera were collected and analyzed for IL-13 and IL-17A using ELISA. Diagnostic utility assessment was performed using receiver operating characteristic (ROC) analysis. The results showed that both cytokines had a significant capacity to differentiate patients with asthma from the control group. The sensitivity and specificity for IL-17A were 97.3% and 52.0%, respectively, whereas for IL-13 it was 81.1% and 52.0%, respectively. Positive predictive values (PPV) were 66.7% and 62.5% for IL-17A and IL-13, respectively. In conclusion, although both biomarkers had low specificity, IL-17A was more sensitive in differentiating children with asthma from those in the control group and had a higher sensitivity rate than IL-13.